Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies

This pilot study is testing a type of personalized immune cell therapy called CAR-T cell therapy (using your own modified immune cells) to treat certain blood cancers that have come back or stopped responding to other treatments. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of a CD19-positive blood cancer, including non-Hodgkin lymphoma, acute lymphoblastic leukemia, or chronic lymphocytic leukemia/Richter's syndrome - Your cancer has come back or stopped responding after at least 2 prior treatment regimens - You are in adequate physical condition with acceptable organ function - You are willing to participate in a 15-year long-term follow-up study **You may NOT be eligible if...** - Your cancer is not confirmed to be CD19-positive - You have not yet tried at least 2 prior lines of treatment - Your organ function does not meet required thresholds - You have uncontrolled infections or other serious medical conditions Talk to your doctor to see if this trial is right for you.